Stock Comparison

JNJ vs MYO

Johnson & Johnson vs Myomo Inc

The Verdict

MYO takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

MYO

Myomo Inc

6.0

out of 10

Solid Pick

Head-to-Head

$557.1B

Market Cap

$54M

26.5

P/E Ratio

-3.8

21.8%

Profit Margin

-36.7%

26.3%

Return on Equity

-114.9%

0.6

Debt-to-Equity

1.0

Conservative

Overall Risk

Aggressive

1.0

DVR Score

6.0

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

MYO6.0/10

Myomo continues to address a large, underserved neurological rehabilitation market with its MyoPro device, validated by strong regulatory clearances and expanding reimbursement. Q1 2026 results, reported on May 9, 2026, exceeded consensus estimates with $10.1M revenue and narrower EPS loss of ($0.07), building on previous operational improvements. The formalization of Horton Capital's 6.0% stake a...

Full MYO Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.